Proteomic Biomarker Discovery in Cerebrospinal Fluid for MS and NMO Differentiation

A proteomic dataset of 3,816 proteins from cerebrospinal fluid (CSF) samples of patients with multiple sclerosis (MS) and neuromyelitis optica (NMO). The data was generated by Mengyang Ding using conventional proteomics and a nanoparticle-based enrichment strategy (LAPE), and validated with ELISA in an independent cohort. The dataset was last updated on 2026-04 30.

Use Cases

• Training binary classifiers to differentiate MS from NMO based on proteomic signatures.
• Identifying disease-specific protein pathways, such as macrophage signaling for MS or hemostasis for NMO.
• Validating candidate biomarkers like CD74 and CD14 using the provided ELISA validation results.
• Exploring low-abundance protein profiles uncovered by the LAPE enrichment strategy.

Strengths

• Deep proteome coverage of 3,816 proteins from cerebrospinal fluid.
• Includes validation results for biomarkers CD74 (AUC 0.75) and CD14 (AUC 0.72) in an independent cohort.
• Generated using two complementary methods: conventional proteomics and a nanoparticle-based low-abundance protein enrichment (LAPE).

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 11.9 KB, indicating limited scope or a summary-level dataset.

Provenance

Source

figshare, author Mengyang Ding.

Collection Method

Comprehensive proteomic analysis of CSF using conventional proteomics and nanoparticle-based LAPE enrichment.

Time Range

null

Freshness

Last updated 2026-04-30 14:34:33; freshness should be verified.

Geography

null